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The rationale of neoadjuvant chemotherapy is to achieve a high rate of response in
patients with locally advanced breast cancer. It also allows earlier assessment of the
sensitivity to antineoplastic drugs based on tumor shrinkage. Obviously, another end-
point of the neoadjuvant approach is to spare as many patients as possible from mas-
tectomy, guaranteeing higher rates of breast-conserving surgery in this setting. The
potential advantage in terms of micrometastatic disease control is also advocated,
even if no data support this theory as yet1.
Rastogi et al.2 have shown that pathological complete response after neoadjuvant
chemotherapy is a prognostic factor for increased survival, especially in patients with
adverse prognostic factors including grade 3 tumors, ER-negative status and/or high
Ki-67. A better ratio between tumor size and breast size seems to be a favorable fac-
tor in the modest increase in the breast-conserving surgery rates after neoadjuvant
chemotherapy, as reported by the NSABP B-18 trial3. 
However, there are still many concerns regarding the neoadjuvant chemotherapy
approach. The first is the lack of upfront pathological staging, also considering that
current imaging is not a reliable surrogate and that the risk of under- or overestima-
tion may not be negligible. The second relevant issue regards the surgical procedure:
obtaining a “real” conservative approach without the clear identification of the site
and extent of disease at the time of resection without clip placement prior to
chemotherapy could be challenging. Margin status can also change in significance af-
ter chemotherapy because tumor shrinkage may be anisotropic. Last but not least,
the determination of radiation volumes and prescription doses after neoadjuvant
chemotherapy remains unclear, especially after a complete pathological response.
The absence of upfront pathological evidence should be taken into account in any
decisions regarding locoregional radiotherapy. Unanswered questions for radiation
oncologists are: a) when to include regional nodes in the treatment volume, and b)
whether a radiation boost to the surgical bed is really useful and when4. Definitive da-
ta on the actual outcome of radiation therapy in this setting are still lacking1.
In the NSABP B-18 and B-27 trials, the 10-year local recurrence rate was higher for
patients having a cN+ status before neoadjuvant chemotherapy and a ypN+ status af-
ter surgery. It must be underlined that regional lymph node irradiation was avoided
in all patients: patients undergoing lumpectomy received breast radiation only, while
patients undergoing mastectomy did not receive any radiation at all. The cumulative
10-year incidence of locoregional recurrence was 12.3% in the mastectomy group and
10.3% in the lumpectomy group, with a high rate of recurrence among patients with
clinical stage ≥III disease regardless of pathological complete response. Several lines
of evidence have demonstrated a beneficial effect of postoperative radiation therapy
on local control and survival5, and extension of the irradiated volumes to the ipsilat-
eral lymph node regions could thus have an impact on the locoregional recurrence
rate6. Based on the findings of these 2 trials, also the possible influence of the boost
remains to be seriously considered in any attempts to reduce the incidence of local
recurrence.
In summary, the uncertainties regarding the volumes and doses of radiation thera-
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py after neoadjuvant chemotherapy and breast surgery
(conservative or not) are still not negligible and deserve
more focused attention not only from radiation oncolo-
gists but all physicians working in the breast team in the
era of the multidisciplinary approach7.
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